Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in Nashville at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from partici
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this prostate cancer clinical trial in Nashville, TN
If you're searching for prostate cancer treatment options in Nashville, TN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.